Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture

Int J Microcirc Clin Exp. 1996 Jul-Aug;16(4):165-9. doi: 10.1159/000179169.

Abstract

In vivo suppression of neovascularization by in situ administration of human recombinant interferon alpha 2a (hrIFN-alpha 2a) was tested on the chick embryo area vasculosa (AV). Methylcellulose discs, each containing 5 IU of hrIFN-alpha 2a were implanted onto the AV at Hamburger-Hamilton (HH) stage 13, and inhibition of blood vessel growth was morphometrically evaluated between HH stages 20 and 27. Our results show: (i) a decreased extent of the AV; (ii) a decreased AV total vessel length; (iii) modified percent ratios of different classes of AV vessels having a definite length. The observed effects of treating with hrIFN-alpha 2a are likely attributable to inhibition of endothelial cell proliferation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Blood Vessels / drug effects
  • Blood Vessels / embryology*
  • Cell Division
  • Chick Embryo / blood supply*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / embryology
  • Interferon alpha-2
  • Interferon-alpha / pharmacology*
  • Recombinant Proteins

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins